The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
=== End of the party === The passing of the Enabling Act did not, as Kaas had suggested, prevent the Centre Party's demise. As promised during the negotiations, a working committee chaired by Hitler and Kaas was supposed to inform about further legislative measures. However, it met only three times (31 March, 2 and 7 April) without any major impact. At that time, the Centre Party was weakened by massive defections by party members. Loyal party members, in particular civil servants, and other Catholic organisations were subject to increasing reprisals, despite Hitler's previous guarantees. The party was also hurt by a declaration of the German bishops that, while maintaining their opposition to Nazi ideology, modified the ban on cooperation with the new authorities. The issue of the concordat prolonged Kaas's stay in Rome, leaving the party without an effective chairman: On 5 May Kaas finally resigned from his post and the party now elected Brüning as his successor. The party adopted a tempered version of the leadership principle; pro-Centre papers now declared that the party's members, or "retinue", would fully submit itself to Brüning. It was not enough, however, to relieve the growing pressure that it and other parties faced in the wake of the process of Gleichschaltung. Prominent members were frequently arrested and beaten, and pro-Centre civil servants were fired. As the summer of 1933 wore on, several government officials—including Papen—demanded that the Centre either dissolve or be closed down by the government.
==== Carbon-oxygen ==== Glucose oxidase (GOX) catalyzes the oxidation of β-D-glucose to D-glucono-δ-lactone with the simultaneous reduction of enzyme-bound flavin. GOX exists as a homodimer, with each subunit binding one FAD molecule. Crystal structures show that FAD binds in a deep pocket of the enzyme near the dimer interface. Studies showed that upon replacement of FAD with 8-hydroxy-5-carba-5-deaza FAD, the stereochemistry of the reaction was determined by reacting with the re face of the flavin. During turnover, the neutral and anionic semiquinones are observed which indicates a radical mechanism.
An amphetamine overdose can result in a stimulant psychosis that may involve a variety of symptoms, such as delusions and paranoia. A Cochrane review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about 5–15% of users fail to recover completely. According to the same review, there is at least one trial that shows antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. Psychosis rarely arises from therapeutic use.
== Cherenkov counting == High-energy beta emitters, such as phosphorus-32 and yttrium-90 can also be counted in a scintillation counter without the cocktail, instead using an aqueous solution containing no scintillators. This technique, known as Cherenkov counting, relies on Cherenkov radiation being detected directly by the photomultiplier tubes. Cherenkov counting benefits from the use of plastic vials which scatter the emitted light, increasing the potential for light to reach the photomultiplier tube.
=== Availability === Cyproheptadine is available widely throughout the world. This includes in Australia, Canada, Europe, Hong Kong, India, Japan, Mexico, Turkey, the United Kingdom, and the United States, among others.
Sources: en.wikipedia.org
Around the time, an expert concludes that "AI art is everywhere right now", with even experts not knowing what it will mean, a news outlet establishes that "AI-generated art booms" and reports about issues of copyright and automation of professional artists, a news outlet investigates how online communities (e.g. their rules) confronted with many such artworks react, a news outlet raised concerns over deepfakes, a magazine highlights possibilities of enabling "new forms of artistic expression", an editorial notes that it may be seen as a welcome "augmentation of human capability". Moreover, additional functionalities – such as enabling the use of user-provided concepts (like an object or a style) learned from few images for novel personalized art generated from the associated word/s (2 Aug) or expanding beyond the borders of artistic images in the same style (31 Aug) – are reported. On 22 August, Stable Diffusion is released as free and open source software.
=== Solvent choice === An eluotropic series, which orders solvents by how much they move compounds, can help select a mobile phase. Solvents are divided into solvent selectivity groups. Using solvents with different elution strengths or different selectivity groups can often give very different results. While single-solvent mobile phases can sometimes give good separation, some cases may require solvent mixtures. In normal-phase TLC, the most common solvent mixtures include ethyl acetate/hexanes (EtOAc/Hex) for less-polar compounds and methanol/dichloromethane (MeOH/DCM) for more polar compounds. Different solvent mixtures and solvent ratios can help give better separation. In reverse-phase TLC, solvent mixtures are typically water with a less-polar solvent: Typical choices are water with tetrahydrofuran (THF), acetonitrile (ACN), or methanol.
=== Optimal solution === The optimal "threading" of a protein sequence onto a known structure and the production of an optimal multiple sequence alignment have been shown to be NP-complete. However, this does not imply that the structural alignment problem is NP-complete. Strictly speaking, an optimal solution to the protein structure alignment problem is only known for certain protein structure similarity measures, such as the measures used in protein structure prediction experiments, GDT_TS and MaxSub. These measures can be rigorously optimized using an algorithm capable of maximizing the number of atoms in two proteins that can be superimposed under a predefined distance cutoff. Unfortunately, the algorithm for optimal solution is not practical, since its running time depends not only on the lengths but also on the intrinsic geometry of input proteins.
== Awards == Archer Martin shared the 1952 Nobel Prize in Chemistry for the invention of partition chromatography with Richard Synge. Archer Martin's 1954 paper with Anthony T. James, "Gas-Liquid Chromatography: A Technique for the Analysis and Identification of Volatile Materials" reported the discovery of gas-liquid chromatography. This was performed at the National Institute for Medical Research in Mill Hill, London, which became the Francis Crick Institute in 2016. It was honoured by a Citation for Chemical Breakthrough Award from the Division of History of Chemistry of the American Chemical Society presented in 2016 to the Francis Crick Institute. Martin was elected a Fellow of the Royal Society in 1950, and made a CBE in 1960.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.